GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Here’s what you need to know. While most people who contract RSV can recover at home, some are sick enough to be admitted to ...

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most ...

Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD.

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

Individuals 65-and-up, particularly those with other health conditions, are among those most-at-risk for severe cases of RSV.

Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.